Literature DB >> 11472316

A study of fructo oligosaccharides in the prevention of travellers' diarrhoea.

J H Cummings1, S Christie, T J Cole.   

Abstract

BACKGROUND: Prebiotic carbohydrates selectively stimulate the growth of bifidobacteria and lactobacilli in the human colon. These bacteria form part of the gut's inherent defence against invading pathogens. AIM: To test the effectiveness of fructo oligosaccharides in preventing travellers' diarrhoea.
METHODS: A total of 244 healthy subjects, travelling to high and medium risk destinations for travellers' diarrhoea, took part in a randomized, double-blind, placebo-controlled study. The protocol comprised a preliminary week for recording bowel habit by diary, a 2-week pre-holiday period with the diary and consumption of 10 g of fructo oligosaccharides or placebo daily, followed by a 2-week holiday with continuation of treatment and diary. A post-study questionnaire was completed by all subjects on their return to the UK.
RESULTS: The consumption of fructo oligosaccharides led to a small (6%; P < 0.02) increase in stool frequency in the pre-holiday period and gave a significantly better sense of 'well-being' during the holiday, although subjects reported more flatulence. There were non-significant decreases in episodes of diarrhoea with 20% on placebo and 11% on fructo oligosaccharides recording episodes in the post-study questionnaire (P=0.08) and 46% placebo, 38% fructo oligosaccharides recording episodes in the diary (P > 0.1). No change in bowel frequency, consistency or stool size was recorded.
CONCLUSION: Travel to high risk areas increases diarrhoea. Fructo oligosaccharides alone are not sufficient to prevent this, although do have some benefits for the subjects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472316     DOI: 10.1046/j.1365-2036.2001.01043.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  15 in total

1.  Carbohydrate metabolism in Bifidobacteria.

Authors:  Karina Pokusaeva; Gerald F Fitzgerald; Douwe van Sinderen
Journal:  Genes Nutr       Date:  2011-02-16       Impact factor: 5.523

Review 2.  Pathogen-induced secretory diarrhea and its prevention.

Authors:  S Anand; S Mandal; P Patil; S K Tomar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-29       Impact factor: 3.267

Review 3.  [Probiotics and prebiotics for the prevention and treatment of atopic eczema].

Authors:  B Bunselmeyer
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

4.  Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial.

Authors:  E Furrie; S Macfarlane; A Kennedy; J H Cummings; S V Walsh; D A O'neil; G T Macfarlane
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

5.  Irritable bowel syndrome: bacteria and inflammation--clinical relevance now.

Authors:  Robin C Spiller
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

6.  Dietary fructo-oligosaccharides and lactulose inhibit intestinal colonisation but stimulate translocation of salmonella in rats.

Authors:  I M J Bovee-Oudenhoven; S J M ten Bruggencate; M L G Lettink-Wissink; R van der Meer
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

7.  The effect of polydextrose and probiotic lactobacilli in a Clostridium difficile-infected human colonic model.

Authors:  Sofia D Forssten; Henna Röytiö; Ashley A Hibberd; Arthur C Ouwehand
Journal:  Microb Ecol Health Dis       Date:  2015-10-13

Review 8.  Fiber and prebiotics: mechanisms and health benefits.

Authors:  Joanne Slavin
Journal:  Nutrients       Date:  2013-04-22       Impact factor: 5.717

Review 9.  The role of probiotics and prebiotics in inducing gut immunity.

Authors:  Angélica T Vieira; Mauro M Teixeira; Flaviano S Martins
Journal:  Front Immunol       Date:  2013-12-12       Impact factor: 7.561

Review 10.  Emergent Sources of Prebiotics: Seaweeds and Microalgae.

Authors:  Maria Filomena de Jesus Raposo; Alcina Maria Miranda Bernardo de Morais; Rui Manuel Santos Costa de Morais
Journal:  Mar Drugs       Date:  2016-01-28       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.